- Home
- RNXT vs TCRX Comparison
RNXT vs TCRX Comparison
Compare RNXT & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RNXT | TCRX |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.4M | 49.4M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RNXT | TCRX |
|---|---|---|
| Price | $1.12 | $0.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $8.25 | $7.00 |
| AVG Volume (30 Days) | 245.7K | ★ 644.9K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.00 | 12.28 |
| EPS | ★ N/A | N/A |
| Revenue | $1,123,000.00 | ★ $10,325,000.00 |
| Revenue This Year | $194.66 | N/A |
| Revenue Next Year | $279.78 | $19.81 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2511.63 | 266.65 |
| 52 Week Low | $0.70 | $0.72 |
| 52 Week High | $1.45 | $2.57 |
Technical Indicators
Market Signals| Indicator | RNXT | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 71.96 | 39.31 |
| Support Level | $0.82 | N/A |
| Resistance Level | $1.28 | $1.16 |
| Average True Range (ATR) | 0.06 | 0.06 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 91.17 | 18.58 |
Price Performance
Historical ComparisonAbout RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.